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Abstract
Tumor cells in ascites are a major source of disease recurrence in ovarian cancer patients. In an attempt to identify and
profile the population of ascites cells obtained from ovarian cancer patients, a novel method was developed to separate
adherent (AD) and non-adherent (NAD) cells in culture. Twenty-five patients were recruited to this study; 11 chemonaive
(CN) and 14 chemoresistant (CR). AD cells from both CN and CR patients exhibited mesenchymal morphology with an
antigen profile of mesenchymal stem cells and fibroblasts. Conversely, NAD cells had an epithelial morphology with
enhanced expression of cancer antigen 125 (CA125), epithelial cell adhesion molecule (EpCAM) and cytokeratin 7. NAD cells
developed infiltrating tumors and ascites within 12–14 weeks after intraperitoneal (i.p.) injections into nude mice, whereas
AD cells remained non-tumorigenic for up to 20 weeks. Subsequent comparison of selective epithelial, mesenchymal and
cancer stem cell (CSC) markers between AD and NAD populations of CN and CR patients demonstrated an enhanced trend
in mRNA expression of E-cadherin, EpCAM, STAT3 and Oct4 in the NAD population of CR patients. A similar trend of
enhanced mRNA expression of CD44, MMP9 and Oct4 was observed in the AD population of CR patients. Hence, using a
novel purification method we demonstrate for the first time a distinct separation of ascites cells into epithelial tumorigenic
and mesenchymal non-tumorigenic populations. We also demonstrate that cells from the ascites of CR patients are
predominantly epithelial and show a trend towards increased mRNA expression of genes associated with CSCs, compared
to cells isolated from the ascites of CN patients. As the tumor cells in the ascites of ovarian cancer patients play a dominant
role in disease recurrence, a thorough understanding of the biology of the ascites microenvironment from CR and CN
patients is essential for effective therapeutic interventions.
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Introduction
In 2009, the American Association for Cancer Research
reported ovarian cancer as the gynecological malignancy with
the highest case-to-mortality ratio [1]. This high mortality rate
results from the diagnosis at an advanced-stage when the cancer
has spread into the peritoneal cavity and metastasized to vital
organs. Ovarian cancer metastasis occurs either directly from the
cortical inclusion cysts of the ovaries or from the fimbrial end of
the fallopian tube [2], and spreads by direct extension to adjacent
organs (for example extraovarian pelvic organs, colon, bladder,
liver, etc), or by the attachment of exfoliated ovarian cancer cells
which survive as cellular aggregates or spheroids. Spheroids are
carried by the peritoneal tumor fluid (ascites) to surrounding
organs in the peritoneal cavity. Extensive seeding of these
spheroids on the uterus, sigmoid colon and omentum is frequently
encountered in advanced-stage and recurrent disease [3].
Current treatment strategies for advanced-stage ovarian cancer
patients result in initial remission in up to 80% of patients [4].
However, after a short remission period (usually 6–22 months)
recurrence occurs in almost all patients [4]. This is largely due to
the ability of tumor cells to evade chemotherapy-associated
cytotoxicity through acquired chemoresistance. Recently, chemo-
resistance has also been associated with the acquisition of epithelial
to mesenchymal transition (EMT) in cancer cells [5–6]. Classically,
EMT enables stationary epithelial cells to become motile and
invasive in order to spread and recolonize into surrounding tissues
[7]. These features of EMT have been shown to correlate with a
CSC-like phenotype [8–9], corroborated recently in clinical cases
by the mesenchymal and ‘tumor initiating’ phenotypes of the
residual tumor cells in breast cancer patients surviving conven-
tional therapy [10]. The phenotype of CSC has been shown to be
dynamically regulated by the tumor microenvironment [11], and
the key feature required for micro and macro-metastatic
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colonization involves not only EMT but also mesenchymal to
epithelial transition (MET) [12–13]. The continuum of EMT and
MET has been described as epithelial mesenchymal plasticity
(EMP) [11]. Such metastatic colonization defines the ability of
EMP transformed disseminated tumor cells to self-renew and
differentiate, the defining cellular traits of CSCs [14].
Although the presence of ascites has been associated with
poor prognosis, the origin and phenotype of cancer cells in
ascites, and its association with chemoresistance and recurrence
is poorly understood. Microscopic inspection of ascites has
previously revealed a complex heterogeneous image consisting
of single cells and spheroids [15]. Non-cancer cells within the
ascites include inflammatory cells, cancer-associated fibroblasts,
immature myeloid cells and activated mesothelial cells, all of
which influence tumor cell behavior and response to chemo-
therapy [16]. Also contributing to the heterogeneity of the
ascites is a population of CSCs that can resist chemotherapy
and give rise to a hierarchy of proliferating tumor cells with
progressive differentiating potential [17,18]. These CSCs, when
purified by sorting and xenografted into nude mice, have been
shown to generate a significantly greater tumor burden
compared to unsorted tumor cells [19], suggesting the greater
tumorigenic potential of CSCs.
Table 1. Description of patients included in the study.
Sample number Stage Age Treatment Status Years survived
1 IIIC 55 chemonaive alive 1 year 3 months
2 unknown 65 MORb trial 1, carboplatin and paclitaxel 6 cycles alive 2 years 1 month
3 IIIc 60 chemonaive alive 3 months
4 IIIc 48 chemonaive deceased 1 year 2 months
5 unknown 80 carboplatin and paclitaxel combination 6 cycles, doxorubicin 1cyle deceased 1 year 6 months
6 IIc 54 chemonaive alive 3 months
7 IIIc 90 chemonaive deceased 1 month
8 IIIc 68 cyclophosphamide 1 cycle, carboplatin and paclitaxel and carboplatin alive 3 years 10 months
9 60 chemonaive alive 6 months
10 IIIc 68 cyclophosphamide 1 cycle, carboplatin and paclitaxel and carboplatin
6 cycles
alive 3 years 10 months
11 IIIc 54 paclitaxel 2 cycles, carboplatin and paclitaxel 3 cycles, doxorubicin
4 cycles AMG 2 cycles, cyclophosphamide 3 cycles
deceased 1 year 8 months
12 IIIc 79 cyclophosphamide 4 cycles, carboplatin
2 cycles, docetaxel 1 cycle
deceased 9 months
13 IIIc 51 docetaxel 3 cycles, unspecified regime 1 cycle, carboplatin and
paclitaxel 6 cycles, doxorubicin 3 cycles, carboplatin 1 cycle,
gemcitabine and carboplatin 6 cycles, docetaxel 3 cycles, topotecan
2 cycles, paclitaxel 4 cycles
deceased 2 years 11 months
14 IIIb 65 carboplatin and paclitaxel combination 6 cycles deceased 3 years
15 IIIc 65 chemonaive alive 1 year 11 months
16 IIIc 56 chemonaive alive 2 years 3 months
17 unknown 54 topotecan 1 cycle, doxorubicin 4 cycles, carboplatin and paclitaxel
combination 6 cycles
alive 4 years 5 months
18 IV 53 chemonaive alive 2 years 4 months
19 unknown 72 chemonaive alive 9 months
20 IIIc 39 MORb trial 6 cycles, doxorubicin 9 cycles, gemcitabine and
carboplatin 2 cycles
deceased 3 years 7 months
21 Ic 33 carboplatin & paclitaxel combination 6 cycles deceased 2 years 9 months
22 IIIc 66 chemonaive alive 11 months
doi:10.1371/journal.pone.0046858.t001
Table 2. Description of the patients recruited for the animal study.
Sample number Stage Age Treatment Status Years survived
1 IIIc 39 MORb trial 6 cycles, doxorubicin 9 cycles, gemcitabine and carboplatin
2 cycles
deceased 3 years 7 months
2 IIIc 68 cyclophosphamide 1, carboplatin and paclitaxel Carboplatin 6 cycles alive 3 years 10 months
3 IIIc 57 Icon7 trial 6 cycles, carboplatin 5 cycles, cyclophosphamide 1 cycle deceased 3 years 11 months
doi:10.1371/journal.pone.0046858.t002
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Figure 1. Morphological features, proliferation and cisplatin sensitivity of NAD and AD cells. (A) NAD spheroids and (B) AD cells were
seeded on low attachment plates immediately after collection. Morphological features of (C) NAD spheroid and (D) AD cells on tissue culture plastic
after 24 h following seeding. Images were assessed by phase contrast microscopy. Magnification was 1006, scale bar = 50 mm. The images are
representative of (n = 25) samples. (E) [3H]-thymidine uptake in AD cells and in cells dispersed from spheroids was performed as described in Methods
and Materials. The graph is a representation of one ascites sample performed in triplicate. (F) Effect of cisplatin on the proliferation {[3H]-thymidine
uptake} of NAD and AD cells obtained from the ascites of ovarian cancer patients. The graph is a representation of three independent experiments,
performed on three independent NAD and AD samples in triplicate. Significantly different between AD versus NAD cells, **p,0.01.
doi:10.1371/journal.pone.0046858.g001
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We hypothesize that recurrence in ovarian cancer patients is
largely dictated by the extent to which the tumor and associated
stromal cells in the peritoneal cavity survive chemotherapy, and
that a comparative mRNA study of the cells isolated from the
ascites of CN versus CR ovarian cancer patients may provide an
important missing link to understanding recurrent disease. The
overall aim of this study was to investigate the differential mRNA
profile of ascites cells from CN and CR patients in order to identify
the gene products that may contribute to the survival and spread
of residual cancer cells following chemotherapy. We also aimed to
understand the metastasizing propensity of the tumor cells in the
ascites of ovarian cancer patients. To achieve this, we developed a
novel purification method to isolate distinct populations of cells
from the ascites of ovarian cancer patients. Using this simple
technique ascites cells were separated in two distinct populations of
cells with well-defined epithelial and mesenchymal phenotypes,
respectively. Cells isolated from CR ascites had a more epithelial
phenotype and showed a trend towards enhanced expression of
genes associated with CSC when compared to cells isolated from
the ascites of CN patients. These results suggest that the ascites
tumor microenvironment may differ in patients before and after
chemotherapy and further may play a role in the relapse of
ovarian cancer patients post-chemotherapy.
Materials and Methods
Antibodies and Reagents
Monoclonal and polyclonal antibodies against CA125, fibro-
blast surface protein (FSP) and CD44 were obtained from Merck
Millipore (MA, USA). Monoclonal antibodies against cytokeratin
7 (cyt 7) and N-cadherin were obtained from Zymed Laboratories
(San Francisco, USA). Polyclonal antibodies against E-cadherin,
vimentin and EpCAM were obtained from Cell Signalling
Technology (Beverly, MA, USA). Polyclonal antibodies against
CD73, CD105, CD90, and CD34 were obtained from Sapphire
Bioscience (NSW, Australia).
Patients
Human ethics statement. Ascites was collected from
patients diagnosed with advanced-stage serous ovarian carcinoma,
after obtaining written informed consent under protocols ap-
proved by the Human Research and Ethics Committee (HREC #
09/09) of The Royal Women’s Hospital, Melbourne, Australia.
The histopathological diagnosis, including tumor grades and
stage were determined by independent staff pathologists as part of
the clinical diagnosis (Table 1). Ascites was obtained from patients
during surgery with primary carcinoma (CN patients). In other
instances, ascites was collected from a group of patients at the time
of recurrence (CR patients). These patients had developed
recurrent disease within 6–20 months of first line of chemother-
apy. Patients in this group were not all treated the same as they
had previously received combinations of chemotherapy consisting
of paclitaxel, carboplatinum and other drugs such as doxorubicin,
gemcitabine, docetaxel, cyclophosphamide and topotecan after
each recurrent episode (Table 1). Samples were collected from
patients during the treatment regimen as described in Table 1.
Preparation of Cells from Ascites of Ovarian Cancer
Patients
The volume of ascites varied between patients. CN patients had
lower ascites volumes (100 ml22L), compared to CR patients
(100 ml217 L). However, in order to standardise the experimen-
tal protocol only 500 ml of ascites was used to collect cells.
Contaminating red blood cells in the cell pellet of ascites were
removed by hypotonic lysis in sterile MilliQ H2O. The bulk of
ascites cells were seeded on low attachment plates (Corning
Incorporated, NY) in MCDB:DMEM (50:50) growth medium
supplemented with fetal bovine serum (10%), glutamine (2 mM)
and penicillin/streptomycin (2 mM) (Life Technologies, CA,
USA). Cells were maintained at 37uC in the presence of 5%
CO2. Under these conditions, NAD cells floated as spheroids in
the medium while AD cells attached to low attachment plates.
After 2–3 days, floating NAD spheroids (dispersed by pipetting)
and AD cells were screened for CA125, EpCAM, cyt 7 and FSP
by flow cytometry. AD cells were maintained in plastic tissue
culture flasks while NAD spheroids were maintained on low
attachment plates. Cells were passaged weekly and experiments
were performed within 1–2 passages.
Cell Counts and Proliferation Assay
AD cells and NAD spheroids collected from 1 ml of ascites were
allowed to adhere on tissue culture plates for 24 h, following
which, cells were trypsinized and counted by Trypan Blue
Exclusion method. The number of AD cells, and cells within the
NAD spheroids were calculated and the percentage of viable cells
in the AD and NAD spheroid populations was evaluated by
calculating the total number of cells present in both AD and NAD
populations of 1 ml of ascites of each patient.
3[H]-Thymidine uptake assay was performed as described
previously [20]. Briefly, 16105 NAD or AD cells were seeded in
triplicate on 24 well plates. After 2, 4 and 6 days, 0.5 mCi of [3H]
thymidine was added to each well, and cells were incubated at
37uC for an additional 16 h. Cells were washed with PBS,
harvested and lysed in 1% Triton and incorporation of [3H]
thymidine was measured by liquid scintillation counting (Hidex
300SL, LKB Instruments, Australia).
For the determination of growth inhibitory concentration
(GI50), 16105 NAD or AD cells were allowed to adhere on 24
well plates for 24 h in triplicate. Both NAD and AD cells were
treated with different concentrations of cisplatin (0.5 mg/ml-
10 mg/ml) for 48 h before the addition of 0.5 mCi of [3H]
thymidine for 16 h. The level of [3H] thymidine incorporation was
determined as described above.
Immunofluorescence Analysis
Immunofluorescence analysis was performed as described
previously [21]. Images were captured using the Leica TCS SP2
laser, and viewed on a HP workstation using the Leica
microsystems TCS SP2 software.
Flow Cytometry Analysis
The flow cytometry method has been described previously [21].
All data were analysed using Cell Quest software (Becton-
Dickinson, Bedford, MA, USA). Results are expressed as mean
intensity of fluorescence (MIF).
RNA Extraction and Quantitative Real Time (q-PCR)
RNA extractions, cDNA synthesis and quantitative determina-
tion of mRNA levels of various genes were performed as described
previously [21]. Sense and antisense primers were designed against
published human sequences for E-cadherin, N-cadherin, Vimen-
tin, Oct4, MMP2, MMP9, EpCAM and CD44. Gel extraction of
PCR products was performed using the QiaEX II Agarose gel
extraction Kit (Qiagen Australia), as per the manufacturer’s
protocol and quantified using the ND-1000 Nanodrop spectro-
photometer (NanoDrop Technologies Inc Wilmington, DE, USA).
Sequences and products were verified as described previously [22].
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Figure 2. Expression of surface markers on NAD and AD cells by flow cytometry. Purified cells from the ascites of CN (n = 11) and CR
(n = 14) ovarian cancer patients were incubated with either control IgG or relevant primary antibodies against the respective antigens followed by
secondary phycoerythrin conjugated antibody. Results are representative of (n = 25) independent samples. The filled histogram in each figure
represents control IgG, black lines indicate protein expression in respective cells.
doi:10.1371/journal.pone.0046858.g002
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Figure 3. Expression and immunolocalization of CA125 and CSC markers by immunofluorescence. Purified NAD and AD cells were
evaluated by immunofluorescence using mouse monoclonal antibody (green) as described in the Methods and Materials. Cellular staining was
visualized using the secondary Alexa 488 (green) fluorescent labeled antibody, and nuclei were detected by DAPI (blue) staining. Images are
representative of three independent samples. Magnification was 2006; scale bar = 50 mm.
doi:10.1371/journal.pone.0046858.g003
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Figure 4. Expression and immunolocalization of MSC markers by immunofluorescence. Immunofluorescence study was performed on
purified NAD and AD cells as described in Figure 3. Images are representative of three independent samples. Magnification was 2006; scale
bar = 50 mm.
doi:10.1371/journal.pone.0046858.g004
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Figure 5. mRNA expression of epithelial, mesenchymal and CSC markers in isolated ascites cells. qPCR was performed on purified NAD
and AD populations as described in the Methods and Materials. Yields were converted to femtograms based on the standard curve for each PCR
product, and the resultant mRNA levels were normalized to the 18S mRNA level per sample. The data were calculated from the results of eight
independent samples assessed in triplicate. Significantly different in AD versus NAD cells *(p,0.05) and **(p,0.01).
doi:10.1371/journal.pone.0046858.g005
Characterization of Ovarian Ascites Tumor Cells
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e46858
Figure 6. Tumorigenic properties of NAD and AD cells purified from the ascites of CR patients. (A) A phase contrast microscope image of
NAD cells adhered to plastic before preparing the cell suspension for i.p. injection; (B) H and E staining of agarose embedded patient sample before
injection; (C) image of solid tumor obtained from a mouse fourteen weeks after i.p. injection of NAD cells (56106); (D) H and E staining of mouse
ascites NAD cells embedded on agarose; (E) Flow cytometric comparison of the expression of CA125, EpCAM and CD44 between the patient’s and
mouse ascites cells. Results are representative of two independent samples. The filled histogram in each figure represents control IgG, black lines
indicate protein expression in human cells, broken lines indicate the expression of the protein in mouse ascites cells.
doi:10.1371/journal.pone.0046858.g006
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Figure 7. H and E staining of tumor and the associated infiltrated organs in a mouse. Histological images of (A) tumor, (B) liver, (C) GI tract
and (D) pancreas from a mouse injected i.p. with NAD cells (56106). Arrows in the tumor (A) indicate pockets of tumor cells surrounded by
connective tissue. (B–D) arrows indicate tumor cells invading the respective organs. H and E staining of (E) kidney and (F) ovary from a mouse
injected with NAD cells (56106). Arrows indicate tumor cells surrounding the organs without invasion. Magnification was 2006 for all, except ovary
which had magnification of 1006, scale bar = 50 mm.
doi:10.1371/journal.pone.0046858.g007
Characterization of Ovarian Ascites Tumor Cells
PLOS ONE | www.plosone.org 10 October 2012 | Volume 7 | Issue 10 | e46858
Primer pairs used include 5–39: E cadherin (Entrez Gene ID 999,
approved symbol CDH1) forward-GGCACAGATGGTGTGAT-
TACAG; reverse- GTCCCAGGCGTAGACCAAGAAA; N-cad-
herin (Entrez Gene ID 1000, approved symbol CADH2) forward-
AAACAGCAAGCACGGGTTA; reverse- CTTAG-
GATTGGGGGCAAAAT; vimentin (Entrez Gene ID 7431,
approved symbol VIM) forward- CCTACAGGAAGCTGCTG-
GAA; reverse- GGTCATCGTGATGCTGAGAA; MMP2 (En-
trez Gene ID 4313, approved symbol MMP2) forward- AAGGG-
GATCCAGGAGCTCTA; reverse-
GCTTGTCACGTGGTGTCACT; MMP9 (Entrez Gene ID
4318, approved symbol MMP9) forward- TTGACAGCGACAA-
GAAGTGG; reverse- GCCATTCAC GTCGTCCTTAT; Ep-
CAM (Entrez Gene ID 4072, approved symbol EpCAM) forward-
CGTCAATGCCAGTGTACTTCAGTT; reverse- TCCAG-
TAGGTTCTCACTCGCTCAG; CD44 (Entrez Gene ID 960,
approved symbol CD44) forward- CCAATGCCTTTGATG-
GACCA; reverse- TGTGAGTGTCCATCTGATTC; Oct4 En-
trez Gene ID 5460, approved symbol POU5F1): forward-
CTCCTGGAGGGCCAGGAATC; reverse- CCA-
CATCGGCCTGTGTATAT; 18S (Entrez Gene ID 100008588,
approved symbol RN18S1) forward-GTAACCCGTTGAACCC-
CATT; reverse-CCATCCAATCGGTAGTAGCG. The mRNA
expression of STAT3 was determined using STAT3 probe
(Applied Biosystems, Victoria, Australia). Real time PCR was
performed using the Applied Biosystems ABI SYBR mix (Victoria,
Australia) using Applied Biosystems ABI 7900 HT Fast real-time
machine. Yields were converted to fg (femtograms) based on the
standard curve for each product and the resulting mRNA levels
were normalized to the 18S mRNA level per sample. Each
experiment was performed independently a minimum of three
times.
Animal Studies
Animal ethics statement. This study was carried out in
strict accordance with the recommendations in the Guide for the
Care and Use of the Laboratory Animals of the National Health
and Medical Research Council of Australia. The experimental
protocol was approved by the Ludwig/Department of Surgery,
Royal Melbourne Hospital and University of Melbourne’s Animal
Ethics Committee (Project-006/11), and was endorsed by the
Research and Ethics Committee of Royal Women’s Hospital
Melbourne, Australia. Female Balb/c nu/nu mice (age, 6–8
weeks) were obtained from the Animal Resources Centre, Western
Australia. Animals were housed in a standard pathogen-free
environment with access to food and water.
NAD and AD cells were isolated from the ascites of three CR
patients (Table 2). 56106 cells per group were injected i.p. with
a 26-gauge needle into ten mice (six with NAD and four with
AD cells). Mice were inspected weekly and tumor progression
was monitored based on overall health and body weight until a
pre-determined endpoint was reached. Endpoint criteria includ-
ed loss of body weight exceeding 20% of initial body weight,
anorexia, general patterns of diminished well being such as
reduced movement and lethargy resulting from lack of interest
in daily activities. Mice were euthanized and organs (such as
liver, stomach, lungs, gastrointestinal tract, pancreas, uterus,
skeletal muscle, colon, kidney, peritoneum, ovaries and spleen),
solid tumors and ascites fluid were collected for further
examination. Metastatic development was documented by a
Royal Women’s Hospital pathologist according to histological
examination (H & E staining) of the organs. Ascites tumor cells
from mice were maintained on low attachment plates and were
embedded on 3% agarose (w/v) for H & E staining. Subsequent
characterization of CA125, EpCAM and CD44 expression in
cells collected from the ascites of mice was performed as
described above.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism
(Version 5; GraphPad Software Inc., San Diego, CA) and
Microsoft Excel. If across the sample set, the means were shown
to have a variation at p,0.05 by the F-test then a parametric t-test
was conducted for unpaired unequal variances. Data was
considered significantly different if p,0.05.
Results
Morphology of Cells Collected from Ascites of Cancer
Patients
Ascites cells derived from both CN (n= 11) and CR patients
(n = 14) were assessed by phase contrast microscopy after seeding
on low attachment plates for 24 h. Two distinct populations of
cells were observed: (i) multicellular aggregates (spheroids) that
floated as three-dimensional structures in the growth medium
without attachment (NAD) (Figure 1A), and (ii) spindle-shaped
fibroblast-like single cells that adhered to the low attachment plates
(AD) (Figure 1 B).
Further morphological assessment of the NAD population
revealed numerous three dimensional clusters of loosely compact-
ed spheroids with a central lumen (Figure 1A). There was a
considerable variation in the morphology and size of spheroids
from different patients as well as within the ascites of the same
patient. In some cases, spheroids were in the form of tight balls
with a defined outer rim, while others displayed loose aggregates of
small cell clusters (Figure 1A). After 24 h culture on tissue culture
plastic, most spheroids attached and a clear transformation from a
three dimensional structure to flattened cellular clusters containing
several layers of adherent cells growing on top of each other was
observed (Figure 1C). The periphery of the spheroids exhibited
elongated cells moving out of the spheroids, whereas cells towards
the centre were more rounded in structure. As the cells moved
Figure 8. Cellular assessment of NAD and AD cells obtained
from CN and CR patients. Percentage distribution of total cells in the
NAD and AD populations of ascites of CN (n = 5) and CR (n = 5) patients
was determined by Trypan Blue Exclusion assay. Results are mean6SEM
of five independent samples assessed in triplicate. Significantly different
in CR versus CN samples, **(p,0.01).
doi:10.1371/journal.pone.0046858.g008
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Figure 9. mRNA expression of selective representative epithelial/mesenchymal markers in isolated cells obtained from CN and CR
patients. qPCR was performed as described in the Methods and Materials on the purified NAD and AD populations of cells isolated from the ascites
of CN (n = 4) and CR (n = 4) ascites samples. Results are expressed as described in Figure 5 for four independent samples assessed in triplicate.
doi:10.1371/journal.pone.0046858.g009
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Figure 10. mRNA expression of selective representative CSC markers in purified ascites cells isolated from CN and CR patients.
qPCR was performed as described in Figure 9 on the purified NAD and AD populations of cells isolated from CN and CR ascites samples. Results are
expressed as described in Figure 9. Significantly different in CR versus CN samples, *(p,0.05).
doi:10.1371/journal.pone.0046858.g010
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away from the central core, cell-cell contact was reduced, resulting
in the disaggregation of the spheroids (Figure 1C). Alternatively,
AD cells attached to the plastic as elongated spindle-like cells and
displayed a fibroblast-like morphology (Figure 1D).
Growth of AD and Spheroid-derived NAD Cells as
Monolayer Cultures
The growth pattern of both AD and NAD cells was determined
in adherent monolayer cultures by 3[H]-thymidine uptake assay.
NAD spheroids were dispersed by pipetting and the growth
Figure 11. mRNA expression of MMP2 and MMP9 in purified cells from CN and CR patients. qPCR was performed on isolated NAD and
AD cells as described in Figure 9. Results are expressed as described in Figure 9. Significantly different in CR versus CN samples, *(p,0.05).
doi:10.1371/journal.pone.0046858.g011
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pattern was compared to AD cells. AD cells had nearly 2-fold
greater growth response compared to cells dispersed from NAD
population (Figure 1E).
Cisplatin Sensitivity of NAD and AD Cells
The cells from NAD spheroids were dispersed by pipetting and
the GI50 value in response to cisplatin was compared to AD cells
isolated from the ascites of ovarian cancer patients (n = 3)
(Figure 1F). Cells within the NAD spheroids were almost 4-fold
more resistant to cisplatin (n = 3, GI50= 8.860.72 mg/ml) com-
pared to AD cells (n = 3, GI50= 2.460.28 mg/ml) (Figure 1 F).
Assessment of Cell Surface Markers by Flow Cytometry
Cell surface expression of FSP, EpCAM, CA125, CD44 and cyt
7 was determined in AD and NAD cells (dispersed by trypsiniza-
tion) by flow cytometry. A high level of expression of EpCAM,
CA125 and cyt 7 was observed in the cells dispersed from the
NAD population, while low/no expression of FSP was detected,
and a relatively low level of expression of CD44 was evident in
NAD spheroids (Figure 2). On the other hand, AD cells were
positive for FSP and CD44, with low/no detectable expression of
CA125 and cytokeratin 7 (Figure 2). Low levels of of EpCAM
expression were detected in AD cells. This pattern of cell surface
marker expression was consistent in all ascites samples (n = 25). No
expression of CD34, CD31 and CD45 was observed in either
NAD or AD populations by flow cytometry.
Analysis of CA125, EpCAM, CD44 and Mesenchymal Stem
Cell Markers by Immunofluorescence
We next analyzed the expression and localization of CA125,
EpCAM, CD44 and mesenchymal stem cell markers in ascites
samples by immunofluorescence. Consistent with the flow
cytometry results, CA125 was undetected in the AD population,
while the cells within the NAD spheroids demonstrated strong
three dimensional diffuse expression of CA125 which was
prominent in the peripheral membranes of some cells (Figure 3).
Very few EpCAM-positive cells were present in the AD population
(Figure 3). In contrast, dense peripheral membrane staining for
EpCAM was observed in almost all NAD spheroids. Diffuse
cytoplasmic staining was present in some spheroids, but the
staining was much stronger on the cells lining the periphery of the
spheroids (Figure 3). On the other hand, the expression of CD44
was confined to the periphery of the NAD spheroids and was
detected in cells that were moving out of spheroids. A strong
staining of CD44 was evident on the membrane of almost all AD
cells (Figure 3).
As stromal fibroblasts and mesenchymal stem cells (MSC) have
been shown to share common properties [23], we assessed the
expression of commonly known MSC markers (CD90, CD73 and
CD105) in both NAD and AD populations of ascites samples
(Figure 4). Scattered diffuse staining of FSP was evident in AD cells
(Figure 4). Few FSP-positive cells were observed in NAD
spheroids, and these were the cells moving out of the spheroids.
Strong expression of CD105 and CD90 was present in AD cells.
The expression of these proteins was detected throughout the
Figure 12. Distribution of markers in isolated cells obtained from the ascites of ovarian cancer patients. The antigens have been scored
as high expression (+++), moderate expression (++), low expression (+), and no expression (2).
doi:10.1371/journal.pone.0046858.g012
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cytoplasm and at the plasma membrane of the cells. Weak
expression of CD73 was present in AD cells. On the other hand,
low/no expression of CD90 and CD73 was observed in NAD
spheroids. However, CD105 staining was evident in very few
scattered cells moving out of the spheroids (Figure 4).
Quantitative Assessment of Selective Representative
Markers at the mRNA Level
To further assess quantitative differences in the expression of
epithelial and mesenchymal markers by the NAD and AD
populations, we compared the mRNA expression levels of some
of the markers by q-PCR. Cells within the NAD spheroids
demonstrated a significantly higher expression level of E-cadherin
and EpCAM compared to AD cells (p,0.01) (Figure 5). On the
other hand, AD cells demonstrated a significantly high mRNA
expression level of vimentin and MMP9 compared to cells within
the NAD spheroids (p,0.01, p,0.05) (Figure 5). The mean
expression of N-cadherin, CD44 and MMP2 appeared higher by
2.5, 7 and 15-fold respectively in the AD population, but no
significance was observed (p,0.2, p,0.06, p,0.17). The expres-
sion of STAT3 and Oct4 was significantly higher in NAD
compared to AD population (p,0.05) (Figure 5).
Assessment of Tumorigenic Potential of NAD and AD
Populations by in vivo Mouse Model
Tumor xenograft experiments were performed to determine the
tumorigenic potential of NAD and AD populations isolated from
the ascites of three CR patients by i.p. inoculation of 56106 NAD
or AD cells per mouse. Five out of the six mice injected with NAD
cells (as a cell suspension) (Figure 6A) developed ascites with solid
tumors (,0.5 cm3) (n = 3) (Figure 6C) or small lesions (n = 2) in the
peritoneum. A tumor latency period of twelve to fourteen weeks
after transplantation was observed. Tumors weighing 0.860.2 g
and ascites (,0.5 ml) were observed in all five mice that developed
tumors (Figure 6C). In contrast, no tumors were observed in mice
(n = 4) injected with the same number of AD cells even twenty
weeks following i.p. injection.
Mice that developed tumors displayed distended abdomens by
nine to eleven weeks suggesting the presence of ascites. Dense,
turbid ascites packed with cells were collected from mice that
developed tumors. Following seeding of the mouse ascites onto low
attachment plates almost all of the cells floated as cellular
aggregates (spheroids) and no adherent population was observed.
Further H & E assessment of mouse ascites cells showed a similar
profile as the donor patient’s spheroid cells (Figures 6B and D). To
elucidate whether the tumorigenic and epithelial profiles of the
patient’s spheroid cells were retained in the ascites of mice, we
assessed the expression of CA125 and EpCAM by flow cytometry.
The expression of CA125 remained relatively unchanged in mouse
ascites cells compared to that of the donor patients (Figure 6E).
However, a slight decrease in the expression of EpCAM and a
corresponding increase in the expression of CD44 were observed
in mouse ascites cells compared to human donor ascites cells
(Figure 6E).
H & E staining of the solid tumors that developed in mice
demonstrated pockets of epithelial spheroids surrounded by
fibrous tissues (Figure 7A). Representative H & E sections of the
Figure 13. A model of tumor cell progression in the ascites of ovarian cancer patients post-chemotherapy. Most ovarian cancer
patients at diagnosis (stage IIIc/IV) present with ascites (CN) which consists of fibroblast-like stromal cells and a very few tumor cells. The majority of
these patients (,80%) after surgery and first line of chemotherapy return with recurrent cancer associated with ascites (CR). During the course of
chemotherapy treatment and subsequent relapses, the percentage of stromal cells in the ascites is gradually decreased and the patient with
recurrent cancer presents with ascites that consists mostly of CA125+++/EpCAM+++/STAT3+++chemoresistant epithelial NAD tumor cells. These
CA125+++/EpCAM+++/STAT3+++ rich tumor cells are the eventual source of extraovarian peritoneal adhesions. These adhesions are the ultimate cause
of patient mortality.
doi:10.1371/journal.pone.0046858.g013
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organs in the peritoneum of mice that developed tumors
demonstrated dissemination of tumor cells in the gastrointestinal
tract, liver and pancreas (Figures 7B–D). In the gastrointestinal
tract, small pockets of differentiated tumor cells surrounded by
fibrous connective tissue were observed, similar to those observed
in the solid tumors (Figure 7C). However, in the pancreas and
liver, tumor cells disseminated by forming an invading edge which
was surrounded by fibrous connective tissue or blood cells
(Figures 7B and D). In the ovary and kidney, tumor cells
surrounded the organs without obvious invasion (Figures 7E and
F). However, no infiltration of tumor cells was observed in the
spleen and skeletal muscle (images not shown).
Cellular Assessment of Selective Representative Markers
in CN and CR Ascites Samples
To better understand the composition of ascites obtained from
CN and CR patients, we next assessed the proportion of NAD and
AD populations in the ascites of CN and CR patients. Ascites from
CR patients (n = 5) was predominantly made up of NAD spheroids
which when dispersed and counted, constituted an average of
,95% of total cells (Figure 8). In CN patients (n = 5) the
proportion of NAD spheroids varied and constituted an average of
25% of total cells (Figure 8) (p,0.05).
q-PCR was performed to further determine whether this
quantitative estimation of NAD spheroid and AD cells in CN
and CR ascites samples conforms to the quantitative expression of
epithelial and mesenchymal markers observed in both populations.
mRNA expression levels of E-cadherin, N-cadherin, vimentin,
EpCAM, Oct4, STAT3, CD44, MMP2 and MMP9 were
determined in the NAD and AD populations of CN (n= 4) and
CR (n= 4) ascites samples. NAD spheroids obtained from CR
patients exhibited characteristics indicative of an epithelial nature
over spheroids derived from CN patients as demonstrated by a 2-
fold enhanced mean expression of E-cadherin (p,0.1), and a
corresponding decrease in the expression of N-cadherin in CR
compared to CN NAD population (Figure 9). The AD cells of both
CN and CR patients had very low expression of E-cadherin, while
there was an enhanced mean expression of N-cadherin in the AD
population of CN patients (,16-fold, p,0.08) compared to CR
patients (Figure 9). The mean expression of vimentin was 2-fold
higher (p,0.1) in the AD cells of CR patients, while no difference
in the expression of vimentin was observed in NAD populations of
CN and CR patients (Figure 9).
We next analyzed the expression of selective representative
CSC markers in the NAD spheroids and AD cells of CN and CR
patients. Compared to CN patients, there was a significantly
enhanced expression of EpCAM in the NAD spheroids of CR
patients (p,0.05) (Figure 10). The expression of Oct4 was
significantly enhanced in the NAD and AD populations of CR
patients compared to CN patients (p,0.05). The NAD spheroids
of CR patients had an enhanced mean expression of STAT3 (2-
fold, p,0.2) compared to CN patients (Figure 10). The mean
mRNA expression of CD44 in the AD cells of CR patients was
approximately 7-fold higher (p,0.08) compared to CN patients
(Figure 10).
Compared to CR patients, a high mean expression of MMP2
(p,0.1) was observed in the AD cells of CN patients, while the
expression of MMP2 was negligible in NAD cells of both CN and
CR patients (Figure 11). Contrary to MMP2 expression, the
expression of MMP9 was significantly higher (p,0.05) in the AD
cells of CR patients (Figure 11). Very low expression of MMP9 was
observed in the NAD cells of CN and CR patients.
Discussion
In this study, we used a simple method to demonstrate the
phenotypic characteristics of two different populations of cells
found in the ascites of patients with advanced-stage serous ovarian
carcinoma. We report for the first time a distinct separation of
ascites cells into NAD epithelial spheroids and AD mesenchymal
cells. Unlike cells grown on plastic (which undergo EMT) NAD
spheroids (EpCAM+++) maintained on low attachment plates
preserved their differentiation status with no loss of epithelial
characteristics observed during the course of the experiments. This
method established to isolate ascites-derived tumor cells from
ovarian cancer patients is distinct from other published methods
which rely on the use of plastic tissue culture ware [24]. This
results in the dedifferentiation of primary human tumor cells to
mesenchymal cells with a consequential loss of in vivo character-
istics. Other methods such as EpCAM-coated [25] or mimetic
peptide-based [26] magnetic beads have also been used to isolate
tumor cells from ascites, but these methods are not only expensive
but time-consuming and result in inconsistent low yields of cells
[25].
We demonstrate that spindle-shaped AD cells isolated from
ascites have enhanced proliferative capacity and shared antigen
profiles in common with stromal fibroblasts (FSP+) and MSC
(CD90, CD105, CD73), consistent with recent studies that
demonstrated similarities between tumor-associated fibroblasts
and MSC [23]. The fact that these cells lacked CA125 expression
and had high expression of N-cadherin and vimentin suggests the
presence of a non-tumorigenic cell population in ascites. In
contrast, the NAD spheroids had high expression of CA125, E-
cadherin and EpCAM consistent with the phenotype of epithelial
tumorigenic cells [27–28]. Low expression of MSC markers was
only observed in cells moving out of the spheroids, suggesting the
induction of EMT and MSC characteristics in disaggregating cells.
Whether this observation is an artifact of culture conditions or is a
representation of the in vivo situation in patients remains to be
established. Notably, sustained incubation of the NAD component
in mouse peritoneum for more than 12 weeks did not lead to a
detectable AD population in vivo.
Tumor-associated MSC have been shown to be derived from
circulatory MSC’s or resident tissue stem cells [29–30], and have
been shown to differentiate into fibroblast-like cells within the
tumor stroma [29]. MSC have also been shown to induce EMT
and CSC in breast tumor cells [31–32], and shown to affect
metastasis [33]. A recent study has reported the tumor promoting
presence of MSC in ovarian tumors [34]. Whether the MSC in the
ascites of ovarian cancer patients have a similar tumor promoting
and EMT initiating roles in patients is yet not known, and is the
subject of ongoing studies.
Quantitative measurement of epithelial and mesenchymal
markers at the mRNA levels indicated that the majority of the
epithelial-specific E-cadherin+++ and EpCAM+++ population
resided within the cells of the NAD spheroids while the
mesenchymal-specific N-Cadherin+++, vimentin+++ and CD44+++
population dominated the AD population. AD cells had high
expression of MMP2 and MMP9, proteases involved with matrix
remodeling during tumor dissemination [35]. MMPs secreted by
tumor-associated fibroblasts have been shown to play a critical role
in ECM degradation during cancer dissemination [35]. In this
context, high expression of MMP2 and MMP9 in the fibroblast-
like AD mesenchymal population was not unexpected. A
schematic diagram of the distribution of these markers in NAD
and AD populations is presented in Figure 12.
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Recently, the existence of CSCs has been shown to play a
significant role in ovarian tumor progression [36,37]. We report
that the NAD epithelial spheroids were rich in endogenous
EpCAM+++, STAT3+++ and Oct4+++ expression, the common
factors/transcription factors distinguished as CSC markers in
recent literature [38–39]. These findings are consistent with recent
studies that have demonstrated the existence of CSCs in the ascites
of ovarian cancer patients [15] [40]. However, a recent study has
reported isolation of mesenchymal cells with stem cell-like
characteristics derived from the ascites in late-stage and recurrent
tumors [24]. The major drawback of this study was that cells were
maintained long-term (,2 months) in adherent cultures in the
presence of EMT promoting growth factors such as epidermal
growth factor and fibroblast growth factor. Hence, the develop-
ment of CSC-like characteristics in mesenchymal cells may be due
to the initiation of EMT by paracrine factors and not the inherent
phenotype of the tumor cells itself.
A xenograft model in which a specific phenotype of human cells
isolated from patients can be propagated into tumors provides an
opportunity to determine the tumorigenic potential of the specific
phenotype of isolated human cells. While subcutaneous mouse
xenograft models have been extensively used for the study of cell
biology and chemotherapy resistance in solid cancers and even in
ovarian cancer [40], their anatomical localization bears little
resemblance to the in vivo scenario of ovarian cancer patients. The
majority of patients with ovarian cancer present with disseminated
intra-peritoneal disease, and metastasis outside the peritoneal
cavity is a rare event [3]. Hence, i.p. mouse xenografts provide an
avenue to determine the pattern of ovarian cancer metastasis to
peritoneal organs. With this objective in mind, an i.p. tumor
xenograft model was established in which the AD and NAD
population of cells isolated from the ascites of three CR patients
were injected i.p. in equal numbers into female nude mice.
Although AD cells did not produce tumors in mice, the NAD
epithelial spheroid cells successfully established xenograft tumors.
The pattern of tumor growth and metastasis reflected by the NAD
spheroids was similar to that observed in advanced-stage ovarian
cancer patients. All tumor-bearing mice developed ascites with
cellular aggregates resembling those of the human donor ascites
samples. Further examination of the mouse ascites derived cellular
aggregates revealed high expression of EpCAM and CA125,
consistent with that of the human donor ascites samples. The
ability to detect CA125 and EpCAM in the ascites of cellular
aggregates of mouse xenografts is reflective of the data that we
have observed in the NAD population of ovarian cancer patients.
The intra-abdominal spread of NAD spheroid cells to GI tract,
pancreas and liver following i.p. inoculation was consistent with
what is seen in advanced-stage ovarian cancer patients (stages III/
IV) [3]. In mouse xenografts, tumor cells adhered to kidney and
ovary but no obvious invasion of tumor into these organs was
observed. However, if given extended time, these adherent cells
may have developed into micro-metastasis as commonly seen in
advanced-stage ovarian cancer patients. Collectively, these find-
ings indicate that the progressive pattern of tumor growth and
metastasis in the mouse xenograft model following the i.p.
inoculation of human epithelial NAD spheroid cells closely
reflected that seen in patients who develop advanced-stage ovarian
cancer which accounts for 70% of ovarian cancer patients seen in
the clinic [41].
It has been shown that the stage and site specific phenotype of
cells within a tumor favor the evolution of a specific phenotype of
tumor cells that not only controls tumor progression but also drug
resistance [42]. Current studies have also shown that residual cells
after chemotherapy treatment secrete soluble factors that provide a
favorable microenvironment to facilitate the growth of residual
cells [43]. This close relationship between chemotherapy-surviving
cells and their secretory microenvironment represent a potential
target for cancer therapy. We and others have recently shown the
evolution of CSC-like cells in ovarian cancer cell population in
response to drug treatment [21][36]. If such is the case, the
presence of CSCs in CR tumors should enhance chemoresistance
and correlate with patient prognosis. We demonstrate that
mesenchymal AD cells are more susceptible to drug treatment
compared to NAD epithelial cells within the spheroids. This may
explain the significantly enhanced proportion of epithelial NAD
cells in CR patients compared to CN patients. The significant
enhanced expression of CSC marker EpCAM on the tumor cells
of CR patients is consistent with the epithelial phenotype of that
population of cells. EpCAM has been shown to be an independent
prognostic marker for reduced survival in ovarian cancer patients
[44]. In addition, metastatic and recurrent tumors were found to
express significantly higher levels of EpCAM when compared with
primary carcinomas [27]. The abundance of EpCAM+++epithelial
spheroids in CR patients may result from abolishment of stromal
components after initial chemotherapy and survival of EpCAM-
rich chemotherapy-treated residual cells in an oxygen and growth
factor rich ascites microenvironment. In this context, facilitation of
rapid proliferation of epithelial cells within the chemotherapy
surviving population may serve as a reservoir of increased tumor
burden, leading to the eventual mortality in recurrent patients
[45]. A conceptual model based on our findings of ovarian tumor
progression in cancer patients is depicted in Figure 13.
Recent literature suggests that tumors rich in activated stromal
cells perpetuate aggressive malignancies [46]. In that scenario, the
reduced stromal component in CR ovarian tumors is consistent
with the non-aggressive nature of ovarian cancer where tumor
growth is localized within the peritoneum microenvironment and
is more dependent on dissemination by adhesion rather than
aggressive invasion through the vasculature. Considering that CR
patients lack, or are low in stromal component, enhanced
expression of CD44 in the stroma of CR patients is intriguing.
As CD44 is involved with the assembly of extracellular matrix
through the regulation of hylauronan, integrins and tetraspanin
family of adhesion molecules [47], one would expect that the
expression of CD44 would be high in CN tumors with a greater
proportion of stromal component. The tumor promoting as well as
tumor initiating potential of CD44 has been observed in many
cancers [47–48]. High expression of CD44 in the stroma of CR
tumors may serve to facilitate either of these functions. Another
interesting finding in this study is the distinct profile of MMP2 and
MMP9 in CN versus CR patients. Although difficult to explain, a
recent study has reported pro-metastatic effects induced by MMP9
in tumor cells and bone marrow derived cells in mouse xenografts
after exposure to certain chemotherapies (taxane-based) [49]. The
expression of MMP2 in that study however remained unchanged.
Our observations in ovarian cancer that the more epithelial
(EpCAM-rich) NAD spheroids exhibit the enhanced malignant
potential in mice and demonstrate an increasing trend of mRNA
expression of selective CSC-like markers, are not entirely
consistent with the relationship that has been developed between
EMT and CSC in mammary cancer [8–9]. However, recent
analysis of EpCAM-low and –high subcomponents in predomi-
nantly basal human mammary cell lines has partitioned certain
aspects of stem-like activity (differentialtion, morphogenic poten-
tial, high drug efflux potential) to the EpCAM high population
resembling luminal progenitor cells, while the EpCAM-low cells
exhibit EMT, invasiveness and mammosphere formation associ-
ated with CSC [50]. This is consistent with the emerging
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association between an altered luminal progenitor profile in basal
breast cancers associated with BRCA1 mutations, rather than the
mesenchymal profile seen in breast CSC. Indeed, association
between increased pluripotency and epithelial subcomponent of
human bladder and prostatic carcinoma cells has recently been
demonstrated [13]. Thus, the relationship between malignant
potential, CSC nature and epithelial mesenchymal plasticity in
different cancer types is an evolving field.
The main finding of this study is the demonstration of a distinct
phenotype of tumor cells (CA125+++EpCAM+++/STAT3+++), as
well as stromal cells (CD44+++/Oct4+++) isolated from the ascites
of a limited number of CR patients (n = 4). Using a novel
purification method we demonstrate for the first time that tumor
cells isolated from the ascites of recurrent ovarian cancer patients
are enriched with EPCAM+++/STAT3+++ tumor cells compared
to cells isolated from the ascites of CN patients. Hence, targeting
EpCAM+++ ovarian tumor cells and/or the associated STAT3
pathway in combination with chemotherapy may help achieve
durable clinical responses in recurrent ovarian cancer patients. In
this context, a recent study has demonstrated that targeting
STAT3 with a small molecule inhibitor can suppress ovarian
cancer growth and potentiate the effect of cisplatin in a mouse
xenograft model [51]. Future studies that elaborate on these
findings in preclinical and clinical settings are needed to develop
strategies for the better management of recurrent ovarian cancer
patients.
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